<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303845</url>
  </required_header>
  <id_info>
    <org_study_id>19-007088</org_study_id>
    <nct_id>NCT04303845</nct_id>
  </id_info>
  <brief_title>Erenumab For Treatment of Hemicrania Continua</brief_title>
  <official_title>Erenumab For Treatment of Hemicrania Continua</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being conducting to learn if the study drug erenumab is successful in
      treating hemicrania continua. The study is also evaluating the safety and tolerability of
      erenumab in individuals being treated for hemicrania continua.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2020</start_date>
  <completion_date type="Anticipated">March 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of participants to have a response rate of 50% or greater reduction of headache frequency after treatment</measure>
    <time_frame>4 weeks post erenumab treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of headaches experienced by participants</measure>
    <time_frame>Baseline, 4 weeks post erenumab treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the amount of total headache hours (with moderate or severe pain) experienced by participants</measure>
    <time_frame>Baseline, 4 weeks post erenumab treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate</measure>
    <time_frame>4 weeks post erenumab treatment</time_frame>
    <description>Number of participants who do not have any occurrence of headache</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemicrania Continua</condition>
  <arm_group>
    <arm_group_label>Treatment with Erenumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects diagnosed with hemicrania continua will receive single dose of Erenumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab</intervention_name>
    <description>140 mg of erenumab via subcutaneous injection</description>
    <arm_group_label>Treatment with Erenumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Adults over the age of 18-66

          -  At least a 12 month history of hemicrania continua (unremitting subtype) according to
             International Classification of Headache Disorders, 3rd Edition (ICHD-3)1

          -  Previous or current complete response to indomethacin

          -  Stable preventive treatment for at least 2 months and no anticipated need to
             adjust/add current headache prevention treatment

        Exclusion Criteria

          -  Nonresponse to a therapeutic dose of indomethacin for hemicrania continua when used
             for at least 1 week

          -  Pregnant or lactating subjects

          -  Use of barbiturate or opioid &gt;6 days per month; history of chronic migraine

          -  History of previous trigeminal-autonomic cephalalgia

          -  History within previous 2 months of interventional procedure for headache (occipital
             or other extracranial nerve block, sphenopalatine ganglion block, cervical facet
             block, facet rhizotomy)

          -  History of cranial nerve/rhizolysis

          -  Botulinumtoxin injection with previous 4 months

          -  Parenteral infusion of or oral corticosteroid use for more than 3 days within 4 weeks
             prior to screening phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rashmi Halker Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Rashmi B. Halker Singh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anencephaly</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erenumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

